​

Rani Therapeutics Ownership | Who Owns Rani Therapeutics?

OverviewForecastRevenueFinancialsChart

Rani Therapeutics Ownership Summary

Rani Therapeutics is owned by 9.52% institutional investors, 5.64% insiders, and 84.84% retail investors. Vanguard group is the largest institutional shareholder, holding 13.98% of RANI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.65% of its assets in Rani Therapeutics shares.

RANI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockRani Therapeutics9.52%5.64%84.84%
SectorHealthcare Stocks 50.44%12.38%37.18%
IndustryBiotech Stocks 48.97%12.07%38.96%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group5.11M13.98%$6.90M
Ra capital management8.50M5.78%$6.25M
Samsara biocapital8.50M5.78%$6.25M
Awm investment company6.50M4.42%$4.78M
Longaeva partners2.33M1.58%$1.71M
Siren2.00M1.36%$1.47M
Geode capital management903.30K0.61%$664.06K
Takeda pharmaceutical203.19K0.56%$101.55K
Blackrock funding, inc. /de556.89K0.38%$409.20K
Bank of america corp /de/91.85K0.35%$349.01K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Takeda pharmaceutical203.19K0.62%$101.55K
Samsara biocapital8.50M0.61%$6.25M
Awm investment company6.50M0.53%$4.78M
Nan fung group493.58K0.30%$362.69K
Lasry marc62.89K0.21%$31.43K
Ra capital management8.50M0.07%$6.25M
Longaeva partners2.33M0.06%$1.71M
Siren2.00M0.04%$1.47M
United services automobile association302.74K0.03%$222.46K
Well done52.01K0.01%$38.22K

Top Buyers

HolderShares% AssetsChange
Vanguard group5.11M0.00%4.22M
Vanguard fiduciary trust455.05K0.00%455.05K
Longaeva partners2.33M0.06%216.02K
Jane street group165.60K-165.60K
Susquehanna group, llp188.22K-131.40K

Top Sellers

HolderShares% AssetsChange
Armistice capital---3.15M
683 capital management---487.17K
Alphabet---448.49K
Millennium management---405.67K
Squarepoint ops16.40K--327.98K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust455.05K0.00%455.05K$334.46K
Jane street group165.60K-165.60K$121.68K
Gsa capital partners llp97.00K0.00%97.00K$71.00K
Vanguard global advisers31.75K-31.75K$23.34K
Traphagen investment advisors22.02K0.00%22.02K$16.18K

Sold Out

HolderChange
Wells fargo & company/mn-103.00
Ameritas advisory services-280.00
Elyxium wealth-760.00
Federated hermes-799.00
Eversource wealth advisors-980.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202646-32.35%14,007,464-68.73%90.06%21-58.82%8700.00%
Dec 31, 20254730.56%23,796,559490.01%6553.46%35150.00%--100.00%
Sep 30, 202535-5.41%4,030,094-36.17%113.69%1440.00%5-28.57%
Jun 30, 202540-6,453,46589.46%1717.02%10-23.08%1066.67%
Mar 31, 202541-6.82%3,609,389-5.48%106.16%13-38.10%620.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.65M3.65%-56.51K
Vanguard Morn Total Stk Mkt Idx Investor3.65M3.65%-56.51K
Vanguard Institutional Extnd Mkt Idx Tr834.89K0.84%-
Fidelity Extended Market Index406.56K0.41%4.20K
Abante Quant Value FI335.25K0.34%128.76K
Tema Obesity & Cardiometabolic ETF105.60K0.32%-
Extended Equity Market Fund E226.79K0.23%207.97K
Extended Equity Market Fund B226.79K0.23%207.97K
Blackrock Extended Mkt Fund CF226.79K0.23%-
iShares Micro-Cap ETF201.70K0.20%-

Recent Insider Transactions

DateNameRoleActivityValue
Jul 21, 2026IMRAN MIR A Buy$24.84K
Mar 27, 2026Javadi Alireza Chief Technical OfficerSell$301.08
Jul 17, 2026Imran Talat Chief Executive OfficerBuy$25.19K
Dec 27, 2024Imran Talat Chief Executive OfficerSell$11.30K
Oct 23, 2025IMRAN MIR A Buy$1.26M

Insider Transactions Trends

DateBuySell
2026 Q32-
2026 Q2--
2026 Q1--
2025 Q422
2025 Q3--

RANI Ownership FAQ

Who Owns Rani Therapeutics?

Rani Therapeutics shareholders are primarily institutional investors at 9.52%, followed by 5.64% insiders and 84.84% retail investors. The average institutional ownership in Rani Therapeutics's industry, Biotech Stocks , is 48.97%, which Rani Therapeutics falls below.

Who owns the most shares of Rani Therapeutics?

Rani Therapeutics’s largest shareholders are Vanguard group (5.11M shares, 13.98%), Ra capital management (8.5M shares, 5.78%), and Samsara biocapital (8.5M shares, 5.78%). Together, they hold 25.54% of Rani Therapeutics’s total shares outstanding.

Does Blackrock own Rani Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Rani Therapeutics.

Who is Rani Therapeutics’s biggest shareholder by percentage of total assets invested?

Takeda pharmaceutical is Rani Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.62% of its assets in 203.19K Rani Therapeutics shares, valued at 101.55K$.

Who is the top mutual fund holder of Rani Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Rani Therapeutics shares, with 3.65% of its total shares outstanding invested in 3.65M Rani Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools